Navigation Links
Simeprevir Administered Once Daily as Part of Combination Therapy Demonstrates Sustained Virologic Response in Treatment-Naive and Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
Date:11/2/2013

WASHINGTON, Nov. 2, 2013 /PRNewswire/ -- Janssen R&D Ireland (Janssen) today announced the presentation of new data at The Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington, DC for the investigational protease inhibitor simeprevir (TMC435) in the treatment of genotype 1 chronic hepatitis C in treatment-naive and treatment-experienced adult patients with compensated liver disease. In analyses of the Phase 3 QUEST-1 and QUEST-2 studies in treatment-naive patients and the Phase 3 PROMISE study in prior relapse patients, the efficacy of simeprevir was observed in hepatitis C patients, including patients with the IL28B TT genotype and METAVIR scores of F4.

"Patients with certain baseline characteristics can be more likely to fail or relapse after prior treatment," said Ira Jacobson, M.D., simeprevir clinical trial investigator, chief of the Division of Gastroenterology and Hepatology, Vincent Astor Distinguished Professor of Medicine, Weill Cornell Medical College, and attending physician, New York-Presbyterian Hospital/Weill Cornell Medical Center. "The breadth of simeprevir data presented at AASLD reinforce its potential as a treatment option for patients and will offer important guidance to physicians once simeprevir is approved."   

On October 24, the U.S. Antiviral Drugs Advisory Committee of the FDA voted unanimously (19-0) to recommend approval of the new drug application filed by Janssen Research & Development, LLC for simeprevir administered once daily with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C virus (HCV) in adult patients with compensated liver disease.

Pooled Analysis from QUEST-1 and QUEST-2 Confirms Clinical Benefit of Simeprevir in Sub-Populations of Patients (Abstract 1122)        
'/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Simeprevir Data in Hepatitis C Patients to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
2. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
3. U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
4. Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
5. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
6. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
7. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
8. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
9. MCOs Shifting Control Over Office-Administered Products from Medical to Pharmacy Benefit, Particularly Affecting Rheumatoid Arthritis Therapies
10. American Journal of Medicine Publishes Hypertension Study Comparing the Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone versus Azilsartan Medoxomil Co-administered with Hydrochlorothiazide
11. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  Strategic Health Services, ... software solutions, today announced a strategic agreement with QualCare, ... New Jersey regional marketplace.  This agreement ... the health and wellness solutions QualCare brings to its ... the surrounding region. QualCare plans cover ...
(Date:12/17/2014)... Dec. 17, 2014  Beamz Interactive, Inc. (OTCQB: ... products, today announced that it has signed an ... and supplier of innovative prosthetic, orthotic and assistive ... of the agreement, RSL Steeper will promote and ... configured for use within UK residential care facilities ...
(Date:12/17/2014)... , Dec. 17, 2014  IGI Laboratories, Inc. ... the closing of its offering of $125 million aggregate ... (the "Notes").  The Notes were offered and sold only ... the Securities Act of 1933, as amended (the "Securities ... fixed rate of 3.75% per year, payable semiannually in ...
Breaking Medicine Technology:Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4
(Date:12/21/2014)... Mi (PRWEB) December 21, 2014 AlignLife ... child in need while at the same time helping people ... is a non-profit community-based organization committed to serving those persons ... meet their needs to improve the quality of life. Dr. ... make an impact in the local community and he knew ...
(Date:12/21/2014)... Phoenix, AZ (PRWEB) December 21, 2014 ... wide range of heating, cooling, plumbing and other similar ... reviews in 2014 with regard to its expert contracting ... an industry leader that has been serving Arizona for ... pride in providing the absolute best in quality customer ...
(Date:12/21/2014)... SCI explores disability in sports ... barriers for disabled athletes with Aaron Scheidies , ... condition called juvenile macular degeneration, where he loses his ... his athletic ambitions to his vision and how he ... pioneer the way for other blind and visually impaired ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 As ... alleging heart attacks, stroke and blood clots from using ... increase, a new study shows that the male hormone ... cancer. In a study published in the Proceedings of ... James Amos-Landgraf examined a group of male rats with ...
(Date:12/21/2014)... The Oncology Institute of Hope and Innovation hosted ... Whittier offices. The Hope for the Holidays Toy Drive is ... their families during the holiday season. This year, the toy ... between both offices. This event continues to be successful year ... team, store managers and assistant managers came out and not ...
Breaking Medicine News(10 mins):Health News:AlignLife of Norton Shores Makes a Brighter Christmas for Kids in Muskegon 2Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 2Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 3Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4
... Reporter , MONDAY, May 7 (HealthDay News) -- If you,re looking ... suggests you can do so by developing a firm purpose in ... make a difference, and it,s possible that the researchers missed another ... who had more purpose -- as defined by the researchers -- ...
... is colonised by E. coli bacteria early in life ... reveals a study of infants carried out at the Sahlgrenska Academy ... gut outnumber the cells in our bodies by a factor of ... the maturation of the immune system. The normal bacterial flora in ...
... men at risk of prostate cancer can be beneficial ... be abandoned, states an article published in CMAJ ... United States Preventive Services Task Force, which last issued ... recommendation against prostate-specific antigen (PSA) screening for men of ...
... long-term follow-up analysis of participants in the Step Study, an ... study participants were at higher risk of becoming infected after ... placebo. The vaccine used in the study did not contain ... were delivered to cells using a vector that employed a ...
... (May 6, 2012) - Eye color may be an indicator ... conditions. A study, led by the University of Colorado School ... to have vitiligo. It then follows, according to scientists, that ... melanoma. Vitiligo is an autoimmune skin disease in which pigment ...
... By Kathleen Doheny HealthDay Reporter , FRIDAY, May ... common than it is in women, but it may be more ... as well as women with breast cancer, and there are opportunities ... surgeon in San Francisco. "They were less likely to get the ...
Cached Medicine News:Health News:Having a 'Purpose in Life' May Help Shield You From Dementia 2Health News:Having a 'Purpose in Life' May Help Shield You From Dementia 3Health News:Gut flora affects maturation of B cells in infants 2Health News:PSA screening to detect prostate cancer can be beneficial to younger and at-risk men 2Health News:Study confirms early elevated HIV infection risk in some Step Study participants 2Health News:Eye color may indicate risk for serious skin conditions 2Health News:Men's Breast Cancer Often More Deadly, Study Suggests 2Health News:Men's Breast Cancer Often More Deadly, Study Suggests 3
... The Self-Cath Closed System is a ... method for safe, simple catheterization designed ... tract infections. It includes a ... The new EasyOff tear tab makes ...
... The Self-Cath family of ... patients a variety of ... Each catheter is ... grade PVC and has ...
Used for intermittent catheterization of a male or female patient to provide drainage of urine from the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
An enzyme-linked immuno-sorbent assay for the detectionand quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Medicine Products: